A former SAC Capital Advisors trader wants to cite in court some 2012 testimony given by the hedge fund's founder Steven Cohen, claiming it rebuts the government's case.» Read More
Actor Stephen Collins continues to make solid gains each day--and he's very consistent in adding $3,000 a day in Bonus Bucks (so that's why we put in his picture). His strategy is paying off as he builds his lead in "Trading With The Stars." Actor Ernie Hudson is making some buys and sells as is Hall of Famer Johnny Bench--who's still in 9th place, but at least he's staying out of the cellar..
Good morning all. Deborah Taft continues to hold the top position, but she is losing ground. And there's a new number two; Jason Kaplan. Jason gains 2nd place on his Worthington Industries trade forcing Chad Mazeika into 3rd place with only small gains on Mariner Energy and Sonus.
Good morning. Deborah Taft and Chad Mazeika maintain their stranglehold on the two top positions of the Leaderboard. Deborah continues in the lead with a portfolio value of $2,585,726.30 up $3k from Tuesday's total of $2,582,726.3 on bonus bucks alone. After Deborah's trade on CVTX she was all in cash before executing two buys Wednesday...
Good morning. Deborah Taft continues in the lead with a portfolio value of $2,582,726.3, up $366,000 Tuesday, from Monday's value of $2,216,726.30. Deborah's gamble on the ever-active CV Therapeutics paid off and secured her lead position. She went all in on Monday with a buy of 300,000 shares of CVTX at $6.75, and it looks like she caught a bottom...
Good morning. Here are the latest names and numbers from Monday's action. Deborah Taft continues in the lead with a portfolio value of $2,216,726.30. Her biggest portfolio gains continue to be in the ever popular Fremont General which she sold out of completely on 3/21. She made $23,062.62 or 1.05% on buying and selling 164,733 shares of Elan Pharma.
Good morning. Deborah Taft stays in the top position with a portfolio value of $2,187,663.68 for a gain of $2,000.00 or 0.09% from Thursday's action. Deborah was all in cash and received $2,000 in bonus bucks and has put the majority of her holdings into Elan Corp. plc (ELN) as of 3/22. (those bonus bucks from the trivia questions do add up!!)
Elan reported a smaller fourth-quarter loss and higher sales Tuesday, citing the expansion of its multiple sclerosis-fighting drug Tysabri as a major factor.
The same rare, but fatal viral infection that forced Biogen Idec and Elan to recall, and recently relaunch, the multiple sclerosis drug, Tysabri, may also be a side effect of Rituxan, also from Biogen Idec and Genentech. In an SEC filing -- not a press release -- and on the FDA website, the companies and the agency disclosed yesterday evening that two people with lupus died after taking Rituxan.